Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? (Q33565496)

28 July 2017

0 references

Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient? (English)

1 reference

28 July 2017

1 reference

0 references

Capell HA

1

1 reference

28 July 2017

Porter DR

series ordinal

2

1 reference

28 July 2017

Madhok R

series ordinal

3

1 reference

28 July 2017

Hunter JA

series ordinal

4

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 June 1993

1 reference

Annals of the Rheumatic Diseases

28 July 2017

published in

1 reference

28 July 2017

volume

52

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

423-428

1 reference

Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Practical results of treatment with disease-modifying antirheumatoid drugs.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Anti-rheumatic drugs and joint damage in rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

A three year follow up of patients allocated to placebo, or oral or injectable gold therapy for rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Effect of sulphasalazine on the radiological progression of rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

A rheumatological dilemma: is it possible to modify the course of rheumatoid arthritis? Can we answer the question?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Slow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1005066

Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy

31 October 2018

1 reference

12 December 2020

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

12 December 2020

The relationship of sulfoxidation status to efficacy and toxicity of penicillamine in the treatment of rheumatoid arthritis

1 reference

12 December 2020

Rheumatoid arthritis: workload and outcome over 10 years

1 reference

12 December 2020

Outcome of parenteral gold therapy in RA patients: a comparison between two periods using life-table analysis

1 reference

12 December 2020

Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.52.6.423

1 reference

28 July 2017

1 reference

28 July 2017

1 reference